| 000 | 00000nam 2200000zi 4500 |
| 001 | 9.896428 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107174320 |
|---|
| 006 | m o d f |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 210210e202105 onc ob f000 0 eng d |
|---|
| 020 | |a9780660374451 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aH164-277/2021E-PDF |
|---|
| 245 | 00|aGuidance document : |bmanagement of drug submissions and applications. |
|---|
| 264 | 1|aOttawa, ON : |bHealth Canada = Santé Canada, |cMay 2021. |
|---|
| 264 | 4|c©2021 |
|---|
| 300 | |a1 online resource (73 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Ligne directrice : gestion des présentations de drogues. |
|---|
| 500 | |a"Pub.: 200421." |
|---|
| 500 | |aIssued also in HTML format. |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 650 | 0|aDrug approval|zCanada. |
|---|
| 650 | 0|aPharmaceutical policy|zCanada. |
|---|
| 710 | 1 |aCanada. |bHealth Canada, |eissuing body. |
|---|
| 775 | 08|tLigne directrice : |w(CaOODSP)9.896429 |
|---|
| 794 | |tGuidance document : |w(CaOODSP)9.901130 |
|---|
| 795 | |tGuidance document : |w(CaOODSP)9.873424 |
|---|
| 856 | 40|qPDF|s669 KB|uhttps://publications.gc.ca/collections/collection_2021/sc-hc/H164-277-2021-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/management-drug-submissions/industry.html |
|---|